DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2125|80|3|581-588

ISSN： 0306-5251

Source： BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.80, Iss.3, 2015-09, pp. : 581-588

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase I Study of Infusional 5-Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan in Japanese Patients with Advanced Colorectal Cancer Who Harbor UGT1A1*1/*1,*1/*6 or *1/*28

By  

Oncology, Vol. 82, Iss. 4, 2012-04 ,pp. : 242-248

Karger

Access to resources Recommend Favorite

A Phase I Study of UGT1A1 *28/*6 Genotype-Directed Dosing of Irinotecan (CPT-11) in Korean Patients with Metastatic Colorectal Cancer Receiving FOLFIRI

By  

Oncology, Vol. 88, Iss. 3, 2014-11 ,pp. : 164-172

Karger

Access to resources Recommend Favorite

Efficacy of Triplet Combination Chemotherapy with Oxaliplatin, Irinotecan and Capecitabine (OCX) in Metastatic Colorectal Cancer in Relation to RAS/RAF Mutation Status: Results of a Retrospective Analysis

By  

Oncology Research and Treatment, Vol. 37, Iss. 11, 2014-10 ,pp. : 646-652

Karger

Access to resources Recommend Favorite

A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of the UGT1A1 and CYP2A6 Polymorphisms on Clinical Activity

By  

Oncology, Vol. 82, Iss. 5, 2012-04 ,pp. : 290-297

Karger

Access to resources Recommend Favorite

Elevated Neutrophil to Lymphocyte Ratio Predicts Poor Prognosis in Advanced Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy

By  

Oncology, Vol. 82, Iss. 5, 2012-04 ,pp. : 261-268

Karger

Access to resources Recommend Favorite